Coherus BioSciences Q4 2022 Earnings Preview
- Coherus BioSciences (NASDAQ:CHRS) is scheduled to announce Q4 earnings results on Monday, March 6th, after market close.
- The consensus EPS Estimate is -$0.69 (-50.0% Y/Y) and the consensus Revenue Estimate is $47.97M (-34.6% Y/Y).
- Over the last 2 years, CHRS has beaten EPS estimates 25% of the time and has beaten revenue estimates 13% of the time.
- Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. Revenue estimates have seen 0 upward revisions and 1 downward.